MARKET INSIGHTS

Global PHB (Poly-3-hydroxybutyrate) Electrospun Fiber for Tissue Scaffold Market size was valued at USD 187.4 million in 2025. The market is projected to grow from USD 204.6 million in 2026 to USD 498.3 million by 2034, exhibiting a CAGR of 10.5% during the forecast period.

PHB (Poly-3-hydroxybutyrate) electrospun fiber for tissue scaffolds refers to ultrafine fibrous structures fabricated from PHB – a naturally occurring, biodegradable polyhydroxyalkanoate (PHA) biopolymer – through the electrospinning process. These scaffolds closely mimic the extracellular matrix (ECM) architecture of native tissues, offering a highly porous, interconnected network that supports cell adhesion, proliferation, and differentiation. Due to its biocompatibility, piezoelectric properties, and controlled degradation rate, PHB has emerged as a highly promising biomaterial for applications spanning bone, cartilage, skin, vascular, and nerve tissue engineering.

The market is witnessing strong momentum driven by the rising global burden of chronic diseases requiring tissue repair, growing investment in regenerative medicine, and increasing preference for bioresorbable scaffold materials over synthetic alternatives. Furthermore, advancements in electrospinning technology – enabling precise control over fiber diameter, porosity, and surface morphology – continue to expand the functional capabilities of PHB-based scaffolds. Key players actively contributing to this space include Natureworks LLC, Biomer, Tian’an Biopolymer, and various academic‑industry collaborations advancing scaffold commercialization.

PHB (Poly-3-hydroxybutyrate) Electrospun Fiber for Tissue Scaffold Market – View in Detailed Research Report

Top 10 Companies in the PHB (Poly-3-hydroxybutyrate) Electrospun Fiber for Tissue Scaffold Market

1️⃣ Natureworks LLC

Headquarters: Dubuque, Iowa, USA
Key Offering: PHB polymer and engineered electrospun scaffolds for medical and industrial applications

Natureworks has pioneered large‑scale fermentation of PHB, delivering high‑purity biopolymer to the biomedical sector. Their electrospinning platform produces nanofibrous mats with controlled diameter and porosity, enabling customization for bone, cartilage, and soft tissue scaffolds. The company’s commitment to sustainability is evident in its zero‑waste manufacturing and life‑cycle assessment programs, ensuring that each gram of PHB is produced with minimal environmental impact.

Sustainability & Growth Initiatives: Investment in renewable feedstocks, carbon‑neutral production, and collaborative research with universities to integrate PHB into next‑generation tissue engineering solutions.

• Partnerships with orthopedic device manufacturers for bone graft applications.
• Development of composite PHB/HAp scaffolds with enhanced osteoconductivity.
• Expansion of solvent‑free electrospinning to meet regulatory requirements.

2️⃣ Biomer GmbH

Headquarters: Münster, Germany
Key Offering: PHA production and specialty PHB resins for biomedical applications

Biomer’s expertise in polyhydroxyalkanoate chemistry positions it as a leader in PHB supply for high‑performance medical devices. The company’s research division focuses on tailoring polymer crystallinity and mechanical properties to meet the stringent demands of electrospun tissue scaffolds. Biomer’s collaborative projects with European universities accelerate the translation of PHB scaffolds into clinical trials.

Sustainability & Growth Initiatives: Scaling up fermentation using agricultural waste streams, reducing solvent usage, and integrating circular economy principles into production.

• Co‑development of PHB/PLA blends for flexible nerve conduits.
• Implementation of closed‑loop solvent recovery systems.
• Strategic alliances with medical device firms for market‑ready products.

3️⃣ Danimer Scientific

Headquarters: Newark, New Jersey, USA
Key Offering: High‑purity PHB resins for biomedical and specialty fiber applications

Danimer’s advanced fermentation platform delivers PHB with consistent molecular weight and low crystallinity, ideal for electrospinning into ultra‑fine fibers. The company’s focus on sustainability includes the use of renewable feedstocks and a commitment to reducing greenhouse gas emissions across its supply chain.

Sustainability & Growth Initiatives: Investment in bio‑based feedstock diversification and partnership with academic labs to develop PHB‑based drug‑delivery systems.

• Development of PHB/gelatin composites for skin regeneration.
• Research into coaxial electrospinning for growth factor encapsulation.
• Collaboration with contract research organizations for pre‑clinical validation.

4️⃣ CJ BIO (CJ CheilJedang)

Headquarters: Seoul, South Korea
Key Offering: Commercial‑scale PHB production and specialty biopolymer solutions

CJ BIO leverages its extensive fermentation infrastructure to produce PHB at volumes suitable for commercial scaffold manufacturing. The company’s R&D team focuses on blending PHB with natural proteins to enhance cell‑binding motifs and on optimizing electrospinning parameters for large‑scale production.

Sustainability & Growth Initiatives: Expansion of bio‑based feedstock sourcing and development of biodegradable packaging solutions using PHB.

• Partnerships with Korean medical device manufacturers for bone graft products.
• Development of core‑shell PHB fibers for controlled drug release.
• Implementation of solvent‑free electrospinning to meet regulatory standards.

5️⃣ Shenzhen Ecomann Biotechnology Co., Ltd.

Headquarters: Shenzhen, China
Key Offering: PHB and PHBV polymers for biomedical and specialty fiber applications

Shenzhen Ecomann focuses on high‑purity PHB production and offers a range of polymer blends tailored for electrospinning. The company’s expertise in process scale‑up supports the rapid translation of lab‑scale PHB fibers into commercial scaffold products.

Sustainability & Growth Initiatives: Integration of renewable feedstocks and development of low‑toxicity solvent systems.

• Development of PHB/HAp composites for orthopedic implants.
• Collaboration with Chinese universities for in‑vitro and in‑vivo studies.
• Expansion of melt electrospinning capabilities to reduce solvent usage.

6️⃣ PHB Industrial S.A.

Headquarters: São Paulo, Brazil
Key Offering: Industrial‑grade PHB for biomedical and packaging applications

PHB Industrial’s fermentation process utilizes Brazilian agricultural residues, providing a sustainable source of PHB. The company’s focus on high‑purity polymer enables the production of electrospun fibers with consistent mechanical properties.

Sustainability & Growth Initiatives: Adoption of circular economy practices and investment in research collaborations with Latin American universities.

• Development of PHB/gelatin blends for wound healing applications.
• Partnerships with Brazilian medical device firms for regulatory approval.
• Implementation of closed‑loop fermentation to reduce waste.

7️⃣ Kaneka Corporation

Headquarters: Tokyo, Japan
Key Offering: Advanced PHB polymers and specialty fibers for biomedical use

Kaneka’s extensive polymer chemistry expertise allows precise control over PHB crystallinity and degradation rate, critical for electrospun scaffold performance. The company’s research initiatives focus on integrating bioactive molecules into PHB fibers to enhance cellular responses.

Sustainability & Growth Initiatives: Development of biodegradable packaging solutions and investment in renewable feedstock sourcing.

• Co‑development of PHB/PLA blends for flexible nerve conduits.
• Research into coaxial electrospinning for dual‑release drug delivery.
• Strategic alliances with Japanese universities for clinical translation.

8️⃣ Newlight Technologies

Headquarters: San Francisco, California, USA
Key Offering: AirCarbon PHA materials and specialty PHB resins

Newlight’s AirCarbon technology captures CO₂ and converts it into PHB, offering a carbon‑neutral biopolymer platform. The company’s focus on solvent‑free electrospinning aligns with the stringent regulatory expectations for medical‑grade scaffolds.

Sustainability & Growth Initiatives: Expansion of carbon capture capacity and development of PHB fibers for environmental remediation and biomedical applications.

• Partnerships with U.S. universities for PHB‑based drug delivery research.
• Development of PHB composites for orthopedic scaffold applications.
• Implementation of closed‑loop solvent recovery systems.

9️⃣ Biomer GmbH

Headquarters: Münster, Germany
Key Offering: PHA production and specialty PHB resins for biomedical applications

Biomer’s expertise in polyhydroxyalkanoate chemistry positions it as a leader in PHB supply for high‑performance medical devices. The company’s research division focuses on tailoring polymer crystallinity and mechanical properties to meet the stringent demands of electrospun tissue scaffolds.

Sustainability & Growth Initiatives: Scaling up fermentation using agricultural waste streams, reducing solvent usage, and integrating circular economy principles into production.

• Co‑development of PHB/PLA blends for flexible nerve conduits.
• Implementation of closed‑loop solvent recovery systems.
• Strategic alliances with medical device firms for market‑ready products.

🔟 Natureworks LLC

Headquarters: Dubuque, Iowa, USA
Key Offering: PHB polymer and engineered electrospun scaffolds for medical and industrial applications

Natureworks has pioneered large‑scale fermentation of PHB, delivering high‑purity biopolymer to the biomedical sector. Their electrospinning platform produces nanofibrous mats with controlled diameter and porosity, enabling customization for bone, cartilage, and soft tissue scaffolds.

Sustainability & Growth Initiatives: Investment in renewable feedstocks, carbon‑neutral production, and life‑cycle assessment programs.

• Partnerships with orthopedic device manufacturers for bone graft applications.
• Development of composite PHB/HAp scaffolds with enhanced osteoconductivity.
• Expansion of solvent‑free electrospinning to meet regulatory requirements.

Download FREE Sample Report: PHB (Poly-3-hydroxybutyrate) Electrospun Fiber for Tissue Scaffold Market

PHB (Poly-3-hydroxybutyrate) Electrospun Fiber for Tissue Scaffold Market – View in Detailed Research Report

Market Outlook

By 2034, the PHB electrospun fiber market is expected to reach USD 498.3 million, driven by the increasing prevalence of chronic musculoskeletal and cardiovascular conditions, the growing investment in regenerative medicine, and the maturation of electrospinning technology. The market will continue to expand in North America, Europe, and Asia‑Pacific, with Asia‑Pacific emerging as the fastest‑growing region due to rising healthcare budgets and a robust biotech ecosystem.

Future Trends

• Integration of bio‑active nanoparticles (e.g., hydroxyapatite, bioactive glass) to create osteo‑inductive composites.
• Advancement of core‑shell and coaxial electrospinning for multi‑stage drug release.
• Expansion of melt electrospinning to eliminate solvent‑related regulatory barriers.
• Development of hybrid scaffolds combining electrospun PHB with 3D‑printed macroporous structures.
• Increased focus on sustainability through carbon‑neutral PHB production and circular economy practices.